AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

United Kingdom-based biopharmaceutical giant AstraZeneca will add 10 to 15 new projects to the company's research and ...

….Link noted a broadening market trend over the past couple of months, indicating that while tech has taken the lead, other ...

Dr Sanjeev Panchal, Country President and MD, AstraZeneca India, stated company's mission to bring innovative medicine faster ...

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

AstraZeneca’s share price has fallen following unfavourable results for one of its new drugs, but others look good, and ...

Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...